Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis

Company Overview

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access.

Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.

Key Stats

• Today's Range: $72.07 to $72.07
• 50-Day Range: $50.14 to $73.31
• 52-Week Range: $49.98 to $135.65
• Volume: 122 shs
• Average Volume: 161 shs
• Market Capitalization: $5.12 billion
• P/E Ratio: 5.06
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

ZLDPF Stock Analysis - Frequently Asked Questions

How have ZLDPF shares performed this year?

Zealand Pharma A/S's stock was trading at $102.36 at the beginning of the year. Since then, ZLDPF shares have decreased by 29.6% and is now trading at $72.07.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its quarterly earnings results on Thursday, August, 14th. The company reported $16.06 earnings per share for the quarter, missing analysts' consensus estimates of $16.72 by $0.66. The company had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $9.18 billion. Zealand Pharma A/S had a trailing twelve-month return on equity of 67.06% and a net margin of 73.90%.

How do I buy shares of Zealand Pharma A/S?

Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/21/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ZLDPF
• Previous Symbol: NASDAQ:ZLDPF
• CIK: 2068427
• Web: www.zealandpharma.com
• Phone: 45-8877-3600
• Fax: 45-8877-3898
• Employees: 340
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): $14.24
• Trailing P/E Ratio: 5.06
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$156.43 million
• Net Margins: 73.90%
• Pretax Margin: 79.78%
• Return on Equity: 67.06%
• Return on Assets: 61.12%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 15.09
• Quick Ratio: 15.08

Sales & Book Value

• Annual Sales: $9.09 million
• Price / Sales: 563.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.59 per share
• Price / Book: 4.10

Miscellaneous

• Outstanding Shares: 71,020,000
• Free Float: N/A
• Market Cap: $5.12 billion
• Optionable: Not Optionable
• Beta: 0.73